Pace has appointed Andrew Fenny as President of Pace Life Sciences to lead the division into its next phase of strategic growth. The company said he will focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
Pharmaceutical and biotechnology organisations continue to face pressure to accelerate development timelines and navigate scientific and regulatory complexity while managing rising costs. Pace Life Sciences aims to help customers address these challenges through seamless service, scientific certainty and comprehensive solutions.
Fenny brings more than two decades of experience across the CDMO and pharmaceutical sectors. He joins Pace Life Sciences from SK Pharmteco, where he served as Chief Commercial Officer. Before that, he worked for Fujifilm Diosynth Biotechnologies as Chief Business Officer.
His background spans commercial strategy, business development, integrated operations and client experience.
Ken Beyer, CEO at Pace, said: “Andy joins Pace at a time when our customers need more than results. They need a partner who can help them navigate complex regulatory pathways and challenging market conditions.”
He added: “Andy’s leadership and expertise will help us deliver the certainty companies need at every stage of the product life cycle because every phase drives programmes closer to patients waiting on treatments that change lives.”
